Phase Ib dose finding and proof-of-concept trial of savolitinib in combination with durvalumab [MEDI-4736] as a second-line treatment in patients with clear renal cell carcinoma
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2016
At a glance
- Drugs Savolitinib (Primary) ; Durvalumab
- Indications Renal cell carcinoma
- Focus Adverse reactions; Proof of concept
- 02 Aug 2016 Status changed from planning to recruiting, according to a Chi-Med media release.
- 15 Oct 2015 New trial record
- 13 Oct 2015 According to a Chi-Med media release, this trial is expected to be initiated by the end of 2015.